Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis.
نویسندگان
چکیده
Drug resistance is a growing public health problem. The World Health Organization reported an estimated 480000 new cases of multidrug-resistant tuberculosis (MDR-TB) worldwide in 2013, of which 9% were estimated to be extensively drug-resistant (XDR)-TB. The prevalence of HIV co-infection among TB patients in the African region is high [1]. In South Africa, 65% of TB patients tested for HIV are HIV-positive [2].
منابع مشابه
Novel drugs against tuberculosis: a clinician's perspective.
The United Nations Millennium Development Goal of reversing the global spread of tuberculosis by 2015 has been offset by the rampant re-emergence of drug-resistant tuberculosis, in particular fluoroquinolone-resistant multidrug-resistant and extensively drug-resistant tuberculosis. After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have bee...
متن کاملClinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis
The emergence of drug-resistant tuberculosis (TB) is a growing problem worldwide. The lack of safe and effective drugs, together with the frequent development of adverse drug reactions can result in worse outcomes. Therefore, new TB drugs able to bolster the current TB treatment regimen are urgently required. Novel drugs that are effective and safe against Mycobacterium tuberculosis are require...
متن کاملTuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5 million deaths reported in 2014. WHO estimates 480,000 cases of these were multidrug resistant (MDR). Less than half of patients who entered into treatment for MDR tuberculosis successfully completed that treatment, mainly due to high mortality and loss to follow-up. These in turn illustrate weakness...
متن کاملOld drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.
Treatment of drug-resistant tuberculosis is hindered by the high toxicity and poor efficacy of second-line drugs. New compounds must be used together with existing drugs, yet clinical trials to optimize combinations of drugs for drug-resistant tuberculosis are lacking. We conducted an extensive review of existing in vitro, animal, and clinical studies involving World Health Organization-defined...
متن کاملBuilding Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries
Current Treatment for Tuberculosis and Research Agenda The standard preferred regimen for the treatment of drug-susceptible tuberculosis (TB) around the world consists of a two-month induction phase of isoniazid, rifampin, pyrazinamide, and ethambutol followed by a continuation phase of four months of isoniazid and rifampin. This regimen has several advantages: (1) it is essentially completely ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The European respiratory journal
دوره 47 2 شماره
صفحات -
تاریخ انتشار 2016